中国神经再生研究(英文版) ›› 2025, Vol. 20 ›› Issue (9): 2583-2584.doi: 10.4103/NRR.NRR-D-24-00616

• 观点:退行性病与再生 • 上一篇    下一篇

巨噬细胞迁移抑制因子治疗肌萎缩侧索硬化症的转化挑战

  

  • 出版日期:2025-09-15 发布日期:2024-12-28

Translational challenges in amyotrophic lateral sclerosis therapy with macrophage migration inhibitory factor

Leenor Alfahel# , Aleksandar Rajkovic# , Adrian Israelson*   

  1. Department of Physiology and Cell Biology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel; The School of Brain Sciences and Cognition, Ben-Gurion University of the Negev, Beer Sheva, Israel
  • Online:2025-09-15 Published:2024-12-28
  • Contact: Adrian Israelson, PhD, adriani@bgu.ac.il
  • Supported by:
    This work was supported by grants from the Israel Science Foundation (ISF #284/19) and German Israeli Foundation (GIF #I-116-415.6-2016) (to AI)

摘要: https://orcid.org/0000-0002-8289-7653 (Adrian Israelson) https://orcid.org/0000-0002-9988-0022 (Leenor Alfahel) https://orcid.org/0000-0003-4878-0598 (Aleksandar Rajkovic)

Abstract: Macrophage migration inhibitory factor (MIF): MIF acts as a pleiotropic inflammatory mediator, playing regulatory roles in innate and adaptive immunity, neuroinflammation, neuroendocrine functions, and nervous system development (Matejuk et al., 2024). In recent years, MIF has attracted significant interest from research groups as a potential target for the treatment of various neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and glioblastoma (Matejuk et al., 2024). Due to its complex biological functions, recent findings suggest that MIF may play contrasting roles in the pathophysiology of various neurodegenerative diseases. Therefore, a precise understanding of MIF’s roles in these diseases could provide crucial insights into better monitoring and potentially treating these conditions.